Beroni Group

Executive Summary

Beroni Group is an Australian-listed biotechnology company advancing a diversified pipeline in oncology, infectious diseases, and regenerative medicine. Its lead asset, PENAO, is a first-in-class mitochondrial ANT inhibitor with potential in a range of solid tumors, currently in preclinical development. The company also develops immune-cell therapies and diagnostic kits for infectious diseases, supported by an e-commerce platform for health products. With $12 million raised and a public listing, Beroni is positioned to progress its preclinical candidates toward the clinic, though it remains at an early stage without revenue from commercial products. The company's broad portfolio offers multiple shots on goal, but execution risks and capital requirements remain significant.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA Filing for PENAO30% success
• Q4 2026Diagnostic Kit Regulatory Submission (e.g., TGA or CE Mark)40% success
• Q2 2026Partnership or Licensing Deal for Immune-Cell Therapy20% success